Resistance Trends in Antimicrobial Susceptibility of Anaerobic Bacteria, Part II

Clinical Microbiology Newsletter

Volumn 33, Issue 2, 2011, Pages 9-15

  Goldstein, Ellie J C ^a,b   Citron, Diane M ^a  

^a Alden Research Laboratory   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM; CEFOTETAN; CEFOXITIN; CLAVULANIC ACID; CLINDAMYCIN; DORIPENEM; DOXYCYCLINE; ERTAPENEM; IMIPENEM; MEROPENEM; METRONIDAZOLE; MINOCYCLINE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULBACTAM; SULTAMICILLIN; TAZOBACTAM; TETRACYCLINE; TIMENTIN;

ABDOMINAL INFECTION; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BINDING AFFINITY; BLOOD CULTURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SKIN INFECTION; SPECIES DIFFERENCE; SPECIES DIVERSITY;

EID: 78650656656     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2010.12.002     Document Type: Article

References (32)

1. Citron D.M., Hecht D.W. Susceptibility test methods: anaerobic bacteria. Manual of clinical microbiology 2011, ASM Press, Washington, DC, In press. 10th ed. J. Versalovic (Ed.).
2. Katsandri A., et al. Two cases of infections due to multidrug-resistant Bacteroides fragilis group strains. J. Clin. Microbiol. 2006, 44:3465-3467.
3. Liu C.-Y., et al. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob. Agents Chemother. 2008, 52:3161-3168.
4. Nagy E., et al. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: twenty years experience. Clin. Microbiol. Infect. 2010, 10.1111/j.1469-0691.2010.03256.x.
5. Snydman D.R., et al. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob. Agents Chemother. 1999, 43:2417-2422.
6. Snydman D.R., et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data. Clin. Infect. Dis. 2010, 50(Suppl. 1):S26-S33.
7. Hecht D.W., Osmolski J.R., O'Keefe J.P. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals. Clin. Infect. Dis. 1993, 16(Suppl. 4):S357-S360.
8. Aldridge K.E., et al. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob. Agents Chemother. 2001, 45:1238-1243.
9. Goldstein E.J.C., Citron D.M., Hecht D.W. Resistance in anaerobic bacteria. Antimicrobial resistance and implications for the 21st century 2008, 207-229. Springer, New York. I.W. Fong, K. Drlica (Eds.).
10. Goldstein E.J.C., et al. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother. 2006, 50:148-155.
11. Jacobus N.V., et al. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob. Agents Chemother. 2004, 48:1034-1036.
12. Goldstein E.J.C., et al. The comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob. Agents Chemother. 2006, 50:3507-3513.
13. Soki J., et al. Molecular characterization of imipenem-resistant, cifA-positive Bacteroides isolates from the USA, Hungary and Kuwait. J. Med. Microbiol. 2004, 53:413-419.
14. Appelbaum P.C., et al. Characterization of a beta-lactamase from Clostridium clostridioforme. J. Antimicrob. Chemother. 1994, 33:33-40.
15. Rasmussen B.A., Bush K., Tally F.P. Antimicrobial resistance in anaerobes. Clin. Infect. Dis. 1997, 24(Suppl. 1):S110-S120.
16. Pumbwe L., et al. Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates. J. Antimicrob. Chemother. 2006, 58:543-548.
17. Snydman D.R., et al. National survey on the susceptibility of Bacteroides fragilis Group: report and analysis of trends for 1997-2000. Clin. Infect. Dis. 2002, 35:S126-S134.
18. Goldstein E.J.C., et al. In vitro activity of 11 antibiotics against 74 anaerobes isolated from pediatric intra-abdominal infections. Anaerobe 2006, 12:63-66.
19. Whittle G., Shoemaker N.B., Salyers A.A. The role of Bacteroides conjugative transposons in the dissemination of antibiotic resistance genes. Cell Mol. Life Sci. 2002, 59:2044-2054.
20. Solomkin J.S., et al. Diagnosis and management of complicated intraabdominal infections in adults and children: guidelines by the Surgical Infection Society and The Infectious Diseases Society of America. Clin. Infect. Dis. 2010, 50:133-164.
21. Nord C.E., Oprica C. Antibiotic resistance in Propionibacterium acnes, microbiological and clinical aspects. Anaerobe 2006, 12:207-210.
22. Gal M., Brazier J.S. Metronidazole resistance in Bacteroides spp. carrying nim genes and the selection of slow-growing metronidazole-resistant mutants. J. Antimicrob. Chemother. 2004, 54:109-116.
23. Oh H., Hedberg M., Edlund C. Efflux-mediated fluoroquinolone resistance in the Bacteroides fragilis group. Anaerobe 2002, 8:277-282.
24. Golan Y., et al. Emergence of fluoroquinolone resistance among Bacteroides species. J. Antimicrob. Chemother. 2003, 52:208-213.
25. Wexler H.M., et al. In vitro activity of moxifloxacin against 179 strains of anaerobic bacteria found in pulmonary infections. Anaerobe 2000, 6:227-231.
26. Edmiston C.E., et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob. Agents Chemother. 2004, 48:1012-1016.
27. Conrads G., Citron D.M., Goldstein E.J.C. Genetic determinant of intrinsic quinolone resistance in Fusobacterium canifelinum. Antimicrob. Agents Chemother. 2005, 49:434-437.
28. Nikolich M.P., Shoemaker N.B., Salyers A.A. A Bacteroides tetracycline resistance gene represents a new class of ribosome protection tetracycline resistance. Antimicrob. Agents Chemother. 1992, 36:1005-1012.
29. Papaparaskevas J., et al. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece. J. Antimicrob. Chemother. 2008, 62:137-141.
30. Glupzynski Y.C., et al. Antimicrobial susceptibility of anaerobic bacteria in Belgium as determined by Etest methodology. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28:261-267.
31. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI document M100-S20 2010, Clinical and Laboratory Standards Institute, Wayne, PA.
32. Citron D.M., et al. Bacteriology of moderate to severe diabetic foot infections and in vitro activity of antimicrobial agents. J. Clin. Microbiol. 2007, 45:2819-2828.